Clinical Trails

Interim results from the phase 2 THIO-101 trial show that the investigational drug ateganosine (THIO), followed by the PD-1 inhibitor cemiplimab (Libtayo), achieved a 90.5% disease control rate in heavily pretreated patients with advanced non-small cell lung cancer (NSCLC). Among 21 patients evaluated, 19 experienced either a complete response, partial response, or stable disease. This […]

Updated results from a Phase 2a clinical trial suggest that namodenoson (CF102), an oral A3 adenosine receptor agonist, may provide lasting disease control for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have already received multiple rounds of treatment. The study met its main safety goal, with no new safety concerns reported in patients receiving

ST-001 SST-001 nanoFenretinide showed promising early results in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, who had limited treatment options. In the Phase 1a trial, 25 heavily pretreated patients received the drug as a daily intravenous infusion for five days every three weeks. The overall response rate

A phase 2 study found that retreating older patients with relapsed multiple myeloma using daratumumab, lenalidomide, and dexamethasone (DRd) remained effective even after previous daratumumab-based treatment. The GMMG-DADA trial enrolled 67 transplant-ineligible patients with a median age of 74, including many with severe kidney disease who are often excluded from clinical trials. During first-line treatment,

Results from the Phase 3 TRIDENT trial showed that starting Tumor Treating Fields (TTFields) at the beginning of chemoradiotherapy did not significantly improve overall survival compared with starting the therapy during the standard maintenance phase for patients with newly diagnosed glioblastoma. The study enrolled 981 patients who received TTFields either alongside radiation and temozolomide chemotherapy

A Phase 2 study presented at the 2026 ESMO Gynaecological Cancers Congress showed that the combination of palbociclib (Ibrance) and anastrozole may provide an effective treatment option for patients with recurrent or metastatic estrogen receptor (ER)-positive, low-grade endometrioid endometrial cancer. Among 25 patients enrolled, the objective response rate was 32% at three months, including one

Bulumtatug fuvedotin (9MW2821), a Nectin-4–targeting antibody-drug conjugate, showed promising activity in patients with recurrent or metastatic cervical cancer who had progressed after platinum-based chemotherapy.. In a phase 1/2 study of 53 patients, 73.6% experienced tumor shrinkage. The confirmed overall response rate was 32.08%, including one complete response and 16 partial responses. Disease control was achieved

Results from the phase 3 POD1UM-303/InterAACT 2 trial have established retifanlimab (Zynyz) combined with carboplatin and paclitaxel as a new first-line treatment for advanced squamous cell carcinoma of the anal canal (SCAC). The findings led the FDA to approve the regimen in May 2025 for patients with inoperable recurrent or metastatic disease who have not

A Phase 3 clinical trial tested sunvozertinib (Zegfrovy), a once-daily oral drug, against standard chemotherapy as first-line treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. The results showed that sunvozertinib worked better than chemotherapy. Patients taking the drug lived longer without their cancer getting worse (about 10.3 months vs. 7.5

Data from the phase 3 SENTRY trial showed that adding selinexor (Xpovio) to ruxolitinib (Jakafi) significantly improved spleen responses in patients with JAK inhibitor-naive myelofibrosis. The study met one of its two co-primary endpoints, with 49.8% of patients receiving the combination achieving at least a 35% reduction in spleen volume at week 24, compared with